By Josh Beckerman
Shares of Tivic Health Systems rose after it discussed briefings provided to senior leadership at the White House and Food and Drug Administration about potential military and defense uses of its product candidates.
The stock was recently up 104% to $7.13 Tuesday. Its intraday range was $6.61 to $13.23. Volume was more than 30.8 million shares, compared with a 65-day average of 1.2 million. Shares are up about 20% this year.
The White House briefing involved the company's TLR5 program, including lead product candidate Entolimod, and the need for advanced treatments for acute radiation syndrome, Tivic said.
The meeting with FDA leadership explored expedited pathways to approval for Entolimod and Entolasta, the company said.
Tivic Chief Operating Officer and President Michael Handley said, "We believe that Entolimod, in particular, is well positioned to fill a critical gap in treating exposure to ionizing radiation and offers several potential advantages over existing approved drugs in the category."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 22, 2025 13:11 ET (17:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.